Q3 2020

Filed Nov 16, 2020 · 10-Q · 47 days after period end · 0001654954-20-012515

Q3 2020 · 10-Q

Revenue—

Net Income

-$3.26M

N/M vs Q3 2019

EPS Diluted

-$0.15

N/M vs Q3 2019

Operating Income-$3,255,450N/M

Operating Cash Flowderived-$2,133,457N/M

Same quarter

Metric	Q3 2020	Q3 2019	Q3 2018	Q3 2017
Revenue	—	$0.00	$0.00	$287.00K
Net Income	-$3.26M	-$3.41M	-$2.76M	-$908.91K
EPS Diluted	-$0.15	-$0.46	-$0.70	-$0.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR